[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,916,676
  • Shares Outstanding, K 125,773
  • Annual Sales, $ 247,000 K
  • Annual Income, $ -353,000 K
  • EBIT $ -398 M
  • EBITDA $ -401 M
  • 60-Month Beta 0.85
  • Price/Sales 12.57
  • Price/Cash Flow N/A
  • Price/Book 5.92

Options Overview Details

View History
  • Implied Volatility 85.85% (+13.01%)
  • Historical Volatility 45.00%
  • IV Percentile 33%
  • IV Rank 17.32%
  • IV High 220.54% on 08/08/25
  • IV Low 57.64% on 05/19/26
  • Expected Move (DTE 11) 2.30 (9.93%)
  • Put/Call Vol Ratio 5.45
  • Today's Volume 71
  • Volume Avg (30-Day) 107
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 7,025
  • Open Int (30-Day) 7,008
  • Expected Range 20.89 to 25.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.01
  • Number of Estimates 4
  • High Estimate $-0.92
  • Low Estimate $-1.04
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.56 +2.79%
on 06/05/26
26.28 -11.76%
on 05/06/26
-2.87 (-11.01%)
since 05/05/26
3-Month
20.00 +15.95%
on 03/30/26
28.72 -19.25%
on 04/22/26
+0.98 (+4.41%)
since 03/05/26
52-Week
7.91 +193.17%
on 06/27/25
28.72 -19.25%
on 04/22/26
+13.56 (+140.81%)
since 06/05/25

Most Recent Stories

More News
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need

RCUS : 23.19 (-6.08%)
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 23.19 (-6.08%)
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first...

RCUS : 23.19 (-6.08%)
Arcus Biosciences: Can the Casdatifan Pivot Justify What's Left of This Valuation?

Barchart Research What to Expect from RCUS Earnings RCUS Generated May 4, 2026 Current Price $26.05 EPS Estimate $$-0.92 Consensus Rating Moderate Buy Average Move 4.64% Arcus Biosciences: Can the Casdatifan...

RCUS : 23.19 (-6.08%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 23.19 (-6.08%)
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 23.19 (-6.08%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 23.19 (-6.08%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 23.19 (-6.08%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 23.19 (-6.08%)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 23.19 (-6.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 26.31
2nd Resistance Point 25.44
1st Resistance Point 24.31
Last Price 23.19
1st Support Level 22.31
2nd Support Level 21.44
3rd Support Level 20.31

See More

52-Week High 28.72
Last Price 23.19
Fibonacci 61.8% 20.77
Fibonacci 50% 18.31
Fibonacci 38.2% 15.86
52-Week Low 7.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.